Eloralintide
NCT06230523
Eli Lilly · Phase 2 · Completed · Enrollment 263
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r | n/r |
| 1 mg Eloralintide | n/r | n/r | n/r | n/r | n/r |
| 3 mg Eloralintide | n/r | n/r | n/r | n/r | n/r |
| 6 mg Eloralintide | n/r | n/r | n/r | n/r | n/r |
| 9 mg Eloralintide | n/r | n/r | n/r | n/r | n/r |
| 6/9 mg Eloralintide | n/r | n/r | n/r | n/r | n/r |
| 3/6/9 mg Eloralintide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.